3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Classical hematology
1
Conditions
Ovarian Neoplasms
56
Fallopian Tube Neoplasms
25
Breast Neoplasms
18
Neoplasms
14
Carcinoma, Ovarian Epithelial
14
Multiple Myeloma
9
Neoplasm Metastasis
7
Triple Negative Breast Neoplasms
3
Recurrence
3
Peritoneal Neoplasms
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Solid Tumors
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Ovarian Cancer Recurrent
2
Liver Neoplasms
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Disease Progression
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Interventions
olaparib
5
talazoparib
1
liposomal doxorubicin
1
iniparib
1
ABT-767
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Fanconi Anemia, Complementation Group D1
×
liposomal doxorubicin
×
Clear all
NCT00628251
2019-12-05
ICEBERG 3
AstraZeneca
Phase 2
Completed
97 enrolled
22 charts